LEADER 01493nam0-2200469li-450 001 990000150680203316 005 20180312154649.0 035 $a0015068 035 $aUSA010015068 035 $a(ALEPH)000015068USA01 035 $a0015068 100 $a19900420d1987----km-y0itay50------ba20001109d1987----km-y0itay0103----ba 101 0 $aita 102 $aIT 105 $aa---||||001yy 200 1 $a<> fabbriche di domani$enuove ipotesi per produrre$fWcevolde Voisin$gprefazione di Philippe Kessler 210 $aMilano$cIl Rostro$dcopyr. 1987 215 $aIX, 148 p.$cill.$d24 cm. 300 $aTrad. a cura di Studio Quattro 312 $aTrad. di: les usines de demain 410 0$12001 454 1$12001$a<> usines de demain.$926914 461 1$1001-------$12001 606 0 $aStabilimenti industriali$xAutomazione 606 0 $aStabilimenti industriali$xGestione 676 $a338.454 700 1$aVOISIN,$bWcevolode$0541698 702 1$aKESSLER,$bPhilippe 801 $aSistema bibliotecario di Ateneo dell' Università di Salerno$bsalbc$gRICA 912 $a990000150680203316 951 $a338.454 VOI$b0000251 951 $aII/100$b467$cII 959 $aBK 969 $aDIMEC 969 $aTEC 979 $c19900420 979 $c20001110$lUSA01$h1712 979 $c20020403$lUSA01$h1622 979 $aPATRY$b90$c20040406$lUSA01$h1611 979 $aDIMEC$b90$c20070126$lUSA01$h1634 996 $aUsines de demain$926914 997 $aUNISA LEADER 04942nam 2201345z- 450 001 9910557666403321 005 20220111 035 $a(CKB)5400000000044842 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/76871 035 $a(oapen)doab76871 035 $a(EXLCZ)995400000000044842 100 $a20202201d2021 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aDrug-Drug Interactions 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2021 215 $a1 online resource (242 p.) 311 08$a3-0365-2035-X 311 08$a3-0365-2036-8 330 $aDrug-drug interactions (DDIs) cause a drug to affect other drugs, leading to reduced drug efficacy or increased toxicity of the affected drug. Some well-known interactions are known to be the cause of adverse drug reactions (ADRs) that are life threatening to the patient. Traditionally, DDI have been evaluated around the selective action of drugs on specific CYP enzymes. The interaction of drugs with CYP remains very important in drug interactions but, recently, other important mechanisms have also been studied as contributing to drug interaction including transport- or UDP-glucuronyltransferase as a Phase II reaction-mediated DDI. In addition, novel mechanisms of regulating DDIs can also be suggested. In the case of the substance targeted for interaction, not only the DDIs but also the herb-drug or food-drug interactions have been reported to be clinically relevant in terms of adverse side effects. Reporting examples of drug interactions on a marketed drug or studies on new mechanisms will be very helpful for preventing the side effects of the patient taking these drugs. This Special Issue aims to highlight current progress in understanding both the clinical and nonclinical interactions of commercial drugs and the elucidation of the mechanisms of drug interactions. 606 $aBiology, life sciences$2bicssc 606 $aResearch & information: general$2bicssc 610 $a(?)-sophoranone 610 $a1A2 610 $a2B6 610 $a2C19 610 $a2C8 610 $a2C9 610 $a2D6 610 $a3A4 610 $aADME 610 $aadverse drug reactions 610 $abiflavonoid 610 $achronic kidney disease 610 $acompetitive inhibition 610 $acomputational prediction 610 $aCYP 610 $aCYP1A1 610 $aCYP1A2 610 $aCYP2C9 610 $aCYP2D6 610 $aCYP3A 610 $aCYP3A4 610 $acytochrome P450 610 $acytochromes P450 610 $aDDI 610 $aDexamethasone 610 $adrug interaction 610 $adrug interactions 610 $adrug metabolism 610 $adrug transporter 610 $adrug-drug interaction 610 $adrug-drug interaction 610 $adrug-drug interactions 610 $adrug-drug interactions 610 $aexpression 610 $afexofenadine 610 $agepants 610 $ahigh plasma protein binding 610 $ain silico 610 $ain vitro 610 $ain vivo 610 $ainhibitor 610 $aixazomib 610 $aKetoconazole 610 $alasmiditan 610 $aLexicomp 610 $alow permeability 610 $aLoxoprofen 610 $amechanism-based inhibition 610 $ametabolic DDI 610 $ametabolism 610 $amigraine 610 $amonoclonal antibodies 610 $anon-competitive inhibition 610 $aO-desmethyltramadol 610 $aOATP1B1 610 $aOATP1B3 610 $aorganic anion transporting polypeptide 1A2 (OATP1A2) 610 $aP-glycoprotein (P-gp) 610 $aP450 610 $apharmacokinetics 610 $aphysiologically-based pharmacokinetics 610 $aplasma concentration 610 $apolypharmacy 610 $apotent inhibition 610 $aQSAR 610 $aregulation 610 $aRumex acetosa 610 $aselamariscina A 610 $asignal detection algorithms 610 $aspontaneous reporting systems 610 $asubset analysis 610 $asubstrate 610 $asystemic exposure 610 $atadalafil 610 $aticagrelor 610 $atissue-specific 610 $atramadol 610 $atyrosine kinase inhibitors 610 $aubiquitination 610 $auridine 5'-diphosphoglucuronosyl transferase 615 7$aBiology, life sciences 615 7$aResearch & information: general 700 $aKim$b Dong Hyun$4edt$01304704 702 $aLee$b Sangkyu$4edt 702 $aKim$b Dong Hyun$4oth 702 $aLee$b Sangkyu$4oth 906 $aBOOK 912 $a9910557666403321 996 $aDrug-Drug Interactions$93027633 997 $aUNINA